A Phase 1, Randomized, Placebo-Controlled Single Ascending Dose Participant- and Investigator-Blind Study to Investigate the Safety, Tolerability, and Pharmacokinetics of UCB5285 in Healthy Study Participants
Latest Information Update: 26 Dec 2025
At a glance
- Drugs UCB 5285 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors UCB Biopharma
Most Recent Events
- 23 Dec 2025 Status changed from not yet recruiting to recruiting.
- 23 Dec 2025 New trial record